Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ: CRBU )

1.070 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Caribou Biosciences Stock Is Crashing Today
Investors didn't like the clinical-stage biotech's Q4 update for one key reason. 
Via The Motley Fool
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
Buy this stock if you're daring, but avoid it for now if you aren't. 
Via The Motley Fool
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
It's less scary to take on risky investments when the market is rising. 
Via The Motley Fool
3 Biotech Stocks You Can Buy and Hold for the Next Decade
These companies are still in the early innings of their growth potential. 
Via The Motley Fool
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Exposures Product Safety
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
2 Top Growth Stocks to Buy Right Now Without Hesitation
These stocks are dirt cheap right now. 
Via The Motley Fool
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
From Caribou Biosciences, Inc.
Via GlobeNewswire
2 Exciting Biotech Stocks to Buy With Less Than $10
You can pick up these stocks for a song right now. 
Via The Motley Fool
Big Pharma Could Transform Into BioTech Pharma
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall... 
Via Benzinga
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Wall Street price targets suggest this stock can rocket more than 400% higher. 
Via The Motley Fool
2 Magnificent Growth Stocks to Buy On the Dip
It might be time to catch these falling knives. 
Via The Motley Fool
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
1 Gene Editing Stock to Buy Now, and 1 to Sell
Target markets matter. So does having the cash to get to them. 
Via The Motley Fool
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.